Clinical Research Directory
Browse clinical research sites, groups, and studies.
CAPA In-vitro Oocyte Maturation (CUHK Medical Centre Limited)
Sponsor: Chinese University of Hong Kong
Summary
In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.
Official title: CAPA In-vitro Oocyte Maturation
Key Details
Gender
FEMALE
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-08-01
Completion Date
2036-07-01
Last Updated
2025-07-24
Healthy Volunteers
Yes
Conditions
Interventions
CAPA-IVM
In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.
Locations (1)
Prince of Wales Hospital
Hong Kong, Hong Kong